Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations

Patrick A. Flume, Peter J. Mogayzel, Karen A. Robinson, Christopher H. Goss, Randall L. Rosenblatt, Robert J. Kuhn, Bruce C. Marshall, Janet Bujan, Anne Downs, Jonathan Finder, Chris Goss, Hector Gutierrez, Leslie Hazle, Mary Lester, Lynne Quittell, Kathryn Sabadosa, Robert L. Vender, Terry B. White, Donna Beth Willey-Courand, Ian SaldanhaModupe Oyegunle, Manjunath B. Shankar, Naomi Mckoy, Shaon Sengupta, Olaide Adebomi Odelola, Sarah Waybright

Research output: Contribution to journalReview articlepeer-review

409 Scopus citations

Abstract

The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)802-808
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume180
Issue number9
DOIs
StatePublished - Nov 1 2009

Keywords

  • Aminoglycosides
  • Drug synergism
  • IV antibiotics
  • Pseudomonas
  • Respiratory therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations'. Together they form a unique fingerprint.

Cite this